Stock Alert for GTx Inc. (GTXI) " />

Stock Alert for GTx Inc. (GTXI)

GTx Inc. (GTXI) engages in the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care and other serious medical conditions. The Company’s newest product candidate is Capesaris (GTx-758), which is being developed for first line treatment of advanced prostate cancer. GTx-758 has the potential to achieve medical castration without causing bone loss or hot flashes. It is also developing Ostarine (GTx-024) and other selective androgen receptor modulators (SARMs) for the prevention and treatment of muscle loss in patients with cancer and for other muscle wasting diseases.  Additionally, GTXI is developing toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy for prostate cancer.GTXI was incorporated in 1997 and is headquartered in Memphis, Tennessee. 

Share Statistics (23-June-11) FY 












Symbol GTXI Revenue, $Mn 14.73 60.61 311.5% 56.58 9.29 -83.6%
Current price $4.63 Gross marg. 91.2% 98.7% 8.2% 99.7% 97.8% -1.9%
52wk Range: $2.27-$6.86 Oper. margin 23.0% -31.2%
Avg Vol (3m): 324,402 Net margin -314.1% 25.2% -108.0% 78.4% -28.0% -135.7%
Market Cap. 239.46M
Shares Outstanding 51.72 EPS, $ -1.27 0.39 -130.7% 1.22 -0.05 -104.1%

Source:, SEC Filings.

Recent News

GTXI saw its shares plummet yesterday after it announced the pricing of its previously announced public offering of its common stock. The cancer drug developer said it intends to sell 10 million shares at $4.75 a share, a 9.2% discount to the stock’s closing price of $5.23 on Wednesday. It said the underwriters would have a 30-day option to buy another 1.5 million shares to cover any over allotments.

Subject to customary closing conditions, the transaction is expected to close on or about June 28. Citi and Jefferies & Co. Inc. have been mandated book-runners and underwriters for the offering.

GTXI expects to raise proceeds of $47.5 million before expenses.  The Company plans to use the net proceeds from the offering for clinical development and other research and development activities and for working capital and general corporate purposes.

Shares were boosted early in the week after the Memphis, Tenn.-based company announced the initiation of a Phase IIb clinical trial evaluating its oral Capesaris tablets against Lupron Depot for first line treatment of advanced prostate cancer.

“Acting selectively through estrogen receptor α, Capesaris has the potential to achieve medical castration without also causing several well documented problems of androgen deprivation therapy for prostate cancer such as hot flashes, bone loss and metabolic syndrome,” Thomas Keane MD, chairman and professor of Urology at the Medical University of South Carolina, and lead investigator of the multicenter Capesaris phase IIb clinical trial, commented in the release.  He said a new form of first line hormonal treatment that avoids some of the side effects of current ADT would be an important development.”

To determine the loading dose of Capesaris required to achieve medical castration in greater than 90% of patients within 28 days, GTXI intends to initiate an additional phase II study in advanced prostate cancer patients in second half of this year.  The Company also plans to advance Capesaris into a phase II study for second line therapy for patients with castration resistant prostate cancer who have failed LHRH therapy.

GTXI lost $0.60 to close Thursday’s trading at $4.63 per share. Nearly 4 million shares have traded hands during the session, versus the 10-day average volume of 282.43K.  The stock has been moving within a range of $2.27 – $6.86 over the past 52-weeks. The stock is currently trading below its 50-day moving average of $5.70 and above its 200-day moving average $3.59.

Visit GTXI at

Financial Summary

GTXI posted a net loss of $2.6 million for the first quarter of 2011, versus a net income of $44.3 million for the same period in 2010.

Revenue for the quarter came in at $9.3 million, down from $56.6 million reported in the same period last year. Revenue for both periods included net sales of FARESTON (toremifene citrate) 60 mg, marketed for the treatment of advanced metastatic breast cancer in postmenopausal women and collaboration revenue from Ipsen Biopharm Ltd. Net sales of FARESTON were $1.2 million and $799,000 for the three months ended March 31, 2011, and 2010, respectively.

Revenue for the first quarter of 2011 included $8.1 million of collaboration revenue as a result of the termination of the Company’s license and collaboration agreement with Ipsen during March 2011. Revenue for the first quarter of 2010 included collaboration revenue of $922,000 from Ipsen and the recognition of $54.9 million of revenue due to the termination in the first quarter of a license and collaboration agreement for the Company’s SARM program.

Research and development expenses for the quarter ended March 31, 2011, were $7.3 million, compared to $7.7 million for the same period in 2010. Research and development expenses for the three months ended March 31, 2011, included a non-cash impairment charge of $1.6 million related to the Company’s toremifene 80 mg intangible asset following the decision to discontinue development of toremifene 80 mg. General and administrative expenses for the quarter were $4.7 million, as against $4.5 million for the same period in 2010.

GTXI’s cash, cash equivalents and short-term investments totaled $49.4 million at March 31, 2011.

Financial Strength (23-June-2011) Company Industry Sector S&P 500
Quick Ratio (MRQ) 15.99 2.70 2.09 0.71
Current Ratio (MRQ) 16.04 3.53 2.63 1.03
LT Debt to Equity (MRQ) 0.00 15.22 23.24 136.67
Total Debt to Equity (MRQ) 0.00 19.25 29.40 182.40
Interest Coverage (TTM) 5.91 1.60 18.18

Source:, SEC Filings.

Analyst Consensus

This is the consensus forecast among four polled investment analysts. Against the GTx Inc company.

Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
Latest 2 0 1 1 0 0
4 weeks ago 2 0 1 1 1 0
2 months ago 1 0 2 1 1 0
3 months ago 0 0 3 1 1 0
Last year 0 0 4 1 1

The one analyst offering a 12-month price target expects GTXI share price to rise to 8.00 in the next year from the last price of 5.23.


Consensus Estimates Analysis

# of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Jun-11 3 1.22 1.30 1.11
Quarter Ending Sep-11 3 1.19 1.30 1.00
Year Ending Dec-11 4 10.42 17.12 4.12 16.41
Year Ending Dec-12 3 14.48 31.88 2.57 21.82
EARNINGS (per share)
Quarter Ending Jun-11 3 -0.18 -0.17 -0.20
Quarter Ending Sep-11 3 -0.20 -0.18 -0.22
Year Ending Dec-11 4 -0.70 -0.60 -0.95 -0.90
Year Ending Dec-12 3 -0.75 -0.55 -0.99 -0.86
LT Growth Rate (%) 1 0.00 0.00 0.00 0.00

Technical Analysis


GTXI is below the lower Bollinger Band, implying that it is currently extended to the downside from its recent trend.

The MACD for GTXI currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of 0, which implies that the underlying moving averages are trending lower.

Comparative Analysis

Company Name Ticker Price per Mrkt. Cap. P/E P/S
June23-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
Novartis AG NVS 59.82 136.75B 10.84 10.44 2.35 2.31
Merck & Co. Inc. MRK 34.97 107.94B 9.38 9.08 2.29 2.31
Eli Lilly & Co. LLY 37.19 41.36B 8.71 10.00 1.76 1.80
Biotechnology Median 19.23 n/a 10.27 n/a
GTx Inc. GTXI 4.63 239.46M n/a n/a 16.84 16.54

Source: Thomson Financial

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at





Leave a Reply

Your email address will not be published. Required fields are marked *